Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the
European Patent Office (EPO) has granted patent EP 2983780 covering the
commercial Cevira[®] device in Europe until 2034.

Cevira is a photodynamic drug-device combination product under development for
non-surgical treatment of high-grade cervical dysplasia. In July 2019, Photocure
announced that it had entered into a License Agreement providing Asieris
Meditech Co., Ltd (Asieris) with a world-wide license to develop and
commercialize Cevira for the treatment of HPV induced cervical precancerous
lesions. In July 2020, Asieris received China NMPA's approval to start a global
Phase III clinical trial for APL-1702 (Cevira).

The EP 2983780 patent covering the commercial Cevira device in Europe, will
expire 09 April 2034.



Notes to editors

About Cevira
Cevira® is a photodynamic drug-device combination product that is being
developed for non-surgical treatment of high-grade cervical dysplasia. Cevira®
is easily placed on the cervix by the gynecologist and removed by the patient,
with no disruption of normal daily activities. Only one or two treatments are
needed.

About Cervical dysplasia
High-grade cervical squamous intraepithelial lesions (HSIL) is a precancerous
condition caused by a persistent HPV infection, a highly prevalent sexually
transmitted disease resulting in approximately 10 million cases with high grade
disease and > 500 000 new cases of cervical cancer each year. In China, 1-2% of
women have HSIL each year. Currently, surgical excision is the most common
treatment option offered to women with cervical high-grade dysplasia. In women
of childbearing age in particular there is a high medical need for a non
-surgical option which preserves the cervical anatomy and function. No such
medical alternative is approved to date.

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com



All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

For further information, please contact:

Photocure

Dan Schneider
President and CEO
Tel: +1-609 759-6515
Email: ds@photocure.com

Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no